Citations

Clear

387 citation(s) found for "Couch, Fergus".

Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis
Carvalho, Marcelo A. , Marsillac, Sylvia M., Karchin, Rachel , Manoukian, Siranoush , Grist, Scott, Swaby, Ramona F., Ürményi, Turán P., Rondinelli, Edson, Gayol, Luis, Baumbach, Lisa, Sutphen, Rebecca , Pickard-Brzosowicz, Jennifer L., Nathanson, Katherine L. , Šali, Andrej , Goldgar, David E., Radice, Paolo , Monteiro, Álvaro N.A. , Silva, Rosane , Couch, Fergus J. , Monteiro, Alvaro N , Radice, Paolo , Nathanson, Katherine L , Manoukian, Siranoush

Mayo Clinic

Cancer Research | February 16, 2007 | Volume: 67 | Issue: 4 | Pages: 1494-1501

10.1158/0008-5472.can-06-3297 | PMID 17308087 Get It

Abstract Germ line inactivating mutations in BRCA1 confer susceptibility for breast and ovarian cancer. However, the relevance of the many missense changes in the gene for which the effect on protein function is unknown remains unclear. Determination of which variants are causally associated with cancer is important for assessment of individual risk. We used a functional assay that measures the transactivation activity of BRCA1 in combination with analysis of protein modeling based on the structure of BRCA1 BRCT domains. In addition, the information generated was interpreted in light of genetic data. We determined the predicted cancer association of 22 BRCA1 variants and verified that the common polymorphism S1613G has no effect on BRCA1 function, even when combined with other rare variants. We estimated the specificity and sensitivity of the assay, and by meta-analysis of 47 variants, we show that variants with <45% of wild-type activity can be classified as deleterious whereas variants with >50% can be classified as neutral. In conclusion, we did functional and structure-based analyses on a large series of BRCA1 missense variants and defined a tentative threshold activity for the classification missense variants. By interpreting the validated functional data in light of additional clinical and structural evidence, we conclude that it is possible to classify all missense variants in the BRCA1 COOH-terminal region. These results bring functional assays for BRCA1 closer to clinical applicability. [Cancer Res 2007;67(4):1494–501]
The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer
Johnson, Michele R., Rabe, Kari G. , Brune, Kieran, Rothenmund, Heidi, Gallinger, Steven , Petersen, Gloria M. , Hruban, Ralph H. , Couch, Fergus J. , Andrade, Mariza de , Goggins, Michael , Klein, Alison P. , Chaffee, Kari G.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 14, 2007 | Volume: 16 | Issue: 2 | Pages: 342-346

10.1158/1055-9965.epi-06-0783 | PMID 17301269 Get It

AbstractMutations in the BRCA2 gene have been implicated in pancreatic cancer susceptibility through studies of high-risk breast and ovarian cancer families. To determine the contribution of mutations in BRCA2 to familial pancreatic cancer, we screened affected probands from 151 high-risk families identified through pancreatic cancer clinics for germ-line BRCA2 mutations. Of these families, 118 had two or more first- and second-degree relatives with pancreatic cancer, and an additional 33 had two or more affected second-degree relatives. The average age of onset for pancreatic cancer was 62.8 years. Five BRCA2 truncating mutations were identified, three in families with two or more first- and second-degree relatives with pancreatic cancer. Three of the families with mutations had a history of breast cancer but not ovarian cancer. Four of five families with mutations were identified through probands with early-onset (<55 years) pancreatic cancer. The results of this study were combined with those from a BRCA2 mutation study of 29 other families from the same Johns Hopkins University National Familial Pancreatic Tumor Registry to estimate the frequency of BRCA2 mutations. A total of 10 carriers from 180 families were identified, suggesting that BRCA2 mutations account for 6% of moderate and high-risk pancreatic cancer families. (Cancer Epidemiol Biomarkers Prev 2007;16(2):342–6)
Truncating Variants in p53AIP1 Disrupting DNA Damage–Induced Apoptosis Are Associated with Prostate Cancer Risk
Wang, Fengwei , Taniguchi, Ken, Seelan, Ratnam S. , Zarfas, Katherine E., McDonnell, Shannon K. , Qian, Chiping , Lu, Youyong , Shridhar, Viji , Tindall, Donald J., Beebe‐Dimmer, Jennifer , Cooney, Kathleen A. , Isaacs, William B., Jacobsen, Steven J. , Schaid, Daniel J. , Thibodeau, Stephen N. , Wang, Xianshu , Wang, Liang , Pan, Kai‐Feng , Couch, Fergus J. , Liu, Wanguo , McDonnell, Shannon K

Mayo Clinic

Cancer Research | November 2, 2006 | Volume: 66 | Issue: 21 | Pages: 10302-10307

10.1158/0008-5472.can-06-0638 | PMID 17079449 Get It

Abstract Germ line mutations in several genes (BRCA1, BRCA2, and CHEK2) whose products are involved in the DNA damage–signaling pathway have been implicated in prostate cancer risk. To identify additional genes in this pathway that might confer susceptibility to this cancer, we analyzed a recently identified DNA damage–response gene, p53AIP1 (a gene encoding for p53-regulated apoptosis-inducing protein 1), for genetic variants in prostate cancer. Five novel germ line variants were identified. The two truncating variants (Ser32Stop and Arg21insG) were found in 3% (4 of 132) of unselected prostate tumor samples. Genotyping of the two variants in an additional 393 men with sporadic prostate cancer showed a frequency of 3.1% (12 of 393) in contrast to 0.6% (2 of 327) in 327 unaffected men (Fisher's exact test, P = 0.018), with an odds ratio (OR) of 5.1 [95% confidence interval (95% CI), 1.1-23.0]. In addition, two of six tumors carrying the truncating variants were associated with loss of heterozygosity of the wild-type alleles, suggesting that p53AIP1 may act as a tumor suppressor. We also showed that the truncated p53AIP1 was unable to induce apoptosis and suppress cell growth in HeLa and COS-7 cells. These results suggest that loss-of-function variants in p53AIP1 associated with the risk of sporadic prostate cancer and further support the concept that the genetic defects in the DNA damage–response genes play an important role in the development of prostate cancer. (Cancer Res 2006; 66(21): 10302-7)
A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
Nibbe, Andrea M. , Visscher, Dan W., Reynolds, Carol, Lingle, Wilma L., Erlander, Mark G. , Ma, Xiao-Jun, Sgroi, Dennis C. , Perez, Edith A. , Goetz, Matthew P. , Suman, Vera J. , Ingle, James N. , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | April 11, 2006 | Volume: 12 | Issue: 7 | Pages: 2080-2087

10.1158/1078-0432.ccr-05-1263 | PMID 16609019 Get It

Abstract Purpose: In the adjuvant treatment of estrogen receptor (ER)–positive breast cancer, additional markers are needed to identify women at high risk for recurrence. Experimental Design: We examined the association between the ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL-17BR) expression and the clinical outcomes of relapse and survival in women with ER-positive breast cancer enrolled onto a North Central Cancer Treatment Group adjuvant tamoxifen trial (NCCTG 89-30-52). Results: Tumor blocks were obtained from 211 of 256 eligible patients, and quantitative reverse transcription-PCR profiles for HOXB13 and IL-17BR were obtained from 206 patients. The cut point for the two-gene log 2(expression ratio) that best discriminated clinical outcome (recurrence and survival) was selected and identified women with significantly worse relapse-free survival (RFS), disease-free survival (DFS), and overall survival (OS), independent of standard prognostic markers. The cut point differed as a function of nodal status [node negative (59th percentile) versus node positive (90th percentile)]. In the node-positive cohort (n = 86), the HOXB13/IL-17BR ratio was not associated with relapse or survival. In contrast, in the node-negative cohort (n = 130), a high HOXB13/IL-17BR ratio was associated with significantly worse RFS [hazard ratio (HR), 1.98; P = 0.031], DFS (HR, 2.03; P = 0.015), and OS (HR, 2.4; P = 0.014), independent of standard prognostic markers. Conclusion: A high HOXB13/IL-17BR expression ratio is associated with increased relapse and death in patients with resected node-negative, ER-positive breast cancer treated with tamoxifen and may identify patients in whom alternative therapies should be studied.
Cancer Risk Assessment at the Atomic Level
Monteiro, Álvaro N.A. , Couch, Fergus J. , Monteiro, Alvaro N

Mayo Clinic

Cancer Research | February 17, 2006 | Volume: 66 | Issue: 4 | Pages: 1897-1899

10.1158/0008-5472.can-05-3034 | PMID 16488985 Get It

Abstract A flurry of articles on the structure of different domains of BRCA1 and BRCA2 have not only shed light on the biology of these proteins but have also raised hopes that these data could eventually be used to infer cancer association for a large number of inherited missense mutations whose effect on protein function is unclear. (Cancer Res 2006; 66(4): 1897-9)
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
Rae, James M. , Safgren, Stephanie L. , Ames, Matthew M. , Visscher, Daniel W., Reynolds, Carol, Lingle, Wilma L., Flockhart, David A., Desta, Zeruesenay , Perez, Edith A. , Goetz, Matthew P. , Suman, Vera J. , Couch, Fergus J. , Ingle, James N. , Safgren, Stephanie L

Mayo Clinic

Journal of Clinical Oncology | December 17, 2005 | Volume: 23 | Issue: 36 | Pages: 9312-9318

10.1200/jco.2005.03.3266 | PMID 16361630 Get It

Purpose Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown. Methods We determined cytochrome P450 (CYP)2D6 (*4 and *6) and CYP3A5 (*3) genotype from paraffin-embedded tumor samples and buccal cells (living patients) in tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast cancer trial. The relationship between genotype and disease outcome was determined using the log-rank test and Cox proportional hazards modeling. Results Paraffin blocks were obtained from 223 of 256 eligible patients, and buccal cells were obtained from 17 living women. CYP2D6 (*4 and *6) and CYP3A5 (*3) genotypes were determined from 190, 194, and 205 patient samples and in 17 living women. The concordance rate between buccal and tumor genotype was 100%. Women with the CYP2D6 *4/*4 genotype had worse relapse-free time (RF-time; P = .023) and disease-free survival (DFS; P = .012), but not overall survival (P = .169) and did not experience moderate to severe hot flashes relative to women heterozygous or homozygous for the wild-type allele. In the multivariate analysis, women with the CYP2D6 *4/*4 genotype still tended to have worse RFS (hazard ratio [HR], 1.85; P = .176) and DFS (HR, 1.86; P = .089). The CYP3A5*3 variant was not associated with any of these clinical outcomes. Conclusion In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with our previous observation that CYP2D6 is responsible for the metabolic activation of tamoxifen to endoxifen.